In LR HCC cells, miR-128-3p mimics strengthened the antiproliferative effects of lenvatinib by directly targeting c-Met, resulting in the downregulation of the ERK/cyclin D1 pathway, which is involved in cell cycle progression. Here, MET is linked to hepatocellular carcinoma.